Trial reportCancer cell2022
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.
Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Cancer cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03066206 (A Phase II Study of Poziotinib in EGFR or HER2 Mutant Advanced Solid Tumors), which is not on this map. Cited by 68 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 2 pooled it
15.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study of Poziotinib in EGFR or HER2 Mutant Advanced Solid Tumors
Who cites it
68 citing papers in PubMed, 2 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature Review.Current oncology (Toronto, Ont.) · 2025Pooled it
- Efficacy and safety of later-line targeted therapies in advanced non-small cell lung cancer with EGFR exon 20 insertion mutations: a systematic review.Frontiers in pharmacology · 2025Pooled it
- Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity.Nature communications · 2025Trial
- New Treatment Strategies for Rare Genomic Alterations:Cancers · 2026Review
- EMTscore infers divergent EMT pathways from omics data and enables rapid screening for EMT-associated gene sets.Bioinformatics (Oxford, England) · 2026Article
- Intestinal Organoid-Based Mathematical Modeling Predicts Clinical Gastrointestinal Toxicity of Oral Oncology Drugs.CPT: pharmacometrics & systems pharmacology · 2026Article
- The resistance landscape of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer: molecular mechanisms and novel therapeutic strategies.Translational lung cancer research · 2026Review
- Therapeutic Advances in Non-Small Cell Lung Cancer HarboringInternational journal of molecular sciences · 2026Review
- EMTscore infers divergent EMT pathways from omics data and enables rapid screening for correlated gene sets.bioRxiv : the preprint server for biology · 2026Article
- A Review on EGFR-Tyrosine Kinase Inhibitors and their Resistance Mechanisms.Current pharmaceutical design · 2026Review
- Precision navigation through the labyrinth: overcoming EGFR resistance in non-Small cell lung cancer.Annals of medicine · 2025Review
- EMT and cancer: what clinicians should know.Nature reviews. Clinical oncology · 2025Review
- Research progress and challenges in the treatment of oncogene-addicted non-small cell lung cancer.Cancer biology & medicine · 2025Review
- Current paradigm of EGFRMed (New York, N.Y.) · 2025Review
- STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Article
- HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs-A Long Way to the Top.Molecules (Basel, Switzerland) · 2025Review
- The present and future of precision oncology and tumor-agnostic therapeutic approaches.The oncologist · 2025Review
- A real‑world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Efficacy and safety outcomes of emerging EGFR‑TKIs for patients with non‑small cell lung cancer with EGFR exon 20 insertion mutations: A systematic review and meta‑analysis.Oncology letters · 2025Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
27 authors at 1 institution in 1 country.
Yasir Y ElaminDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, PO Box 301402, 1500 Holcombe Boulevard, Houston, TX 77030, USA.
Jacqulyne P RobichauxDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, PO Box 301402, 1500 Holcombe Boulevard, Houston, TX 77030, USA.
Brett W CarterDepartment of Thoracic Imaging, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Mehmet AltanDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, PO Box 301402, 1500 Holcombe Boulevard, Houston, TX 77030, USA.
Hai TranDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, PO Box 301402, 1500 Holcombe Boulevard, Houston, TX 77030, USA.
Don L GibbonsDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, PO Box 301402, 1500 Holcombe Boulevard, Houston, TX 77030, USA.
Simon HeekeDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, PO Box 301402, 1500 Holcombe Boulevard, Houston, TX 77030, USA.
Frank V FossellaDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, PO Box 301402, 1500 Holcombe Boulevard, Houston, TX 77030, USA.
Vincent K LamDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, PO Box 301402, 1500 Holcombe Boulevard, Houston, TX 77030, USA; Department of Medicine, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD 21287, USA.
Xiuning LeDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, PO Box 301402, 1500 Holcombe Boulevard, Houston, TX 77030, USA.
Marcelo V NegraoDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, PO Box 301402, 1500 Holcombe Boulevard, Houston, TX 77030, USA.
Monique B NilssonDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, PO Box 301402, 1500 Holcombe Boulevard, Houston, TX 77030, USA.
Anisha PatelDepartment of Dermatology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
R S K VijayanInstitute for Applied Cancer Science, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Jason B CrossInstitute for Applied Cancer Science, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Jianjun ZhangDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, PO Box 301402, 1500 Holcombe Boulevard, Houston, TX 77030, USA.
Lauren A ByersDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, PO Box 301402, 1500 Holcombe Boulevard, Houston, TX 77030, USA.
Charles LuDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, PO Box 301402, 1500 Holcombe Boulevard, Houston, TX 77030, USA.
Tina CasconeDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, PO Box 301402, 1500 Holcombe Boulevard, Houston, TX 77030, USA.
Lei FengDepartment of Biostatistics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Rajyalakshmi LuthraDepartment of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Francis A San LucasDepartment of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Geeta ManthaDepartment of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
Mark RoutbortDepartment of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
George BlumenscheinDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, PO Box 301402, 1500 Holcombe Boulevard, Houston, TX 77030, USA.
Anne S TsaoDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, PO Box 301402, 1500 Holcombe Boulevard, Houston, TX 77030, USA.
John V HeymachDepartment of Thoracic/Head and Neck Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Unit 432, PO Box 301402, 1500 Holcombe Boulevard, Houston, TX 77030, USA. Electronic address: jheymach@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MUNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V., MINNA, JOHN D. · 1996 to 2024
$57.4MUCSF Project 1U54CA224081 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Trever G Bivona, Jack Roth · 2017 to 2026
$12.9MUniversity of Texas PDX Development and Trial CenterU54CA224065 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DAMODARAN, SENTHILKUMAR, MERIC-BERNSTAM, FUNDA · 2017 to 2022
$7.7MMolecular features impacting drug resistance in atypical EGFR exon 18 and exon 20 mutant non-small cell lung cancers and the development of novel mutant-selective inhibitorsR01CA247975 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEYMACH, JOHN V., JONES, PHILIP · 2020 to 2024
$2.8MTherapeutic strategies against EGFR exon 20 mutant lung cancerR01CA234183 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEYMACH, JOHN V., WONG, KWOK KIN · 2020 to 2024
$2.8MOvercoming Resistance to Anti-EGFR Therapy by Drug RepurposingR01CA190628 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FANG, BINGLIANG, HEYMACH, JOHN V. · 2015 to 2019
$2.6MTargeting EGFR mutant tyrosine kinase inhibitors (TKIs) resistant and drug-tolerant persister cells in non-small cell lung cancer (NSCLC)R50CA265307 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI NILSSON, MONIQUE B · 2021 to 2025
$585kNCI NIH HHS P30 CA016672NCI NIH HHS P50 CA070907NCI NIH HHS R01 CA190628NCI NIH HHS R01 CA234183NCI NIH HHS R01 CA247975NCI NIH HHS R50 CA265307NCI NIH HHS U54 CA224065NCI NIH HHS U54 CA224081
Abstract
We report a phase II study of 50 advanced non-small cell lung cancer (NSCLC) patients with point mutations or insertions in EGFR exon 20 treated with poziotinib (NCT03066206). The study achieved its primary endpoint, with confirmed objective response rates (ORRs) of 32% and 31% by investigator and blinded independent review, respectively, with a median progression-free survival of 5.5 months. Using preclinical studies, in silico modeling, and molecular dynamics simulations, we found that poziotinib sensitivity was highly dependent on the insertion location, with near-loop insertions (amino acids A767 to P772) being more sensitive than far-loop insertions, an observation confirmed clinically with ORRs of 46% and 0% observed in near versus far-loop, respectively (p = 0.0015). Putative mechanisms of acquired resistance included EGFR T790M, MET amplifications, and epithelial-to-mesenchymal transition (EMT). Our data demonstrate that poziotinib is active in EGFR exon 20-mutant NSCLC, although this activity is influenced by insertion location.
Indexed as
Carcinoma, Non-Small-Cell LungLung NeoplasmsDrug Resistance, NeoplasmErbB ReceptorsExonsHumansMutationProtein Kinase InhibitorsQuinazolinesTreatment OutcomeEGFR protein, humanErbB ReceptorsHM781-36BProtein Kinase InhibitorsQuinazolinesepidermal growth factor receptorexon 20 insertionnon-small cell lung carcinoma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03066206ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.